» Articles » PMID: 38761257

Bone Metabolism in Diabetes: a Clinician's Guide to Understanding the Bone-glucose Interplay

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2024 May 18
PMID 38761257
Authors
Affiliations
Soon will be listed here.
Abstract

Skeletal fragility is an increasingly recognised, but poorly understood, complication of both type 1 and type 2 diabetes. Fracture risk varies according to skeletal site and diabetes-related characteristics. Post-fracture outcomes, including mortality risk, are worse in those with diabetes, placing these people at significant risk. Each fracture therefore represents a sentinel event that warrants targeted management. However, diabetes is a very heterogeneous condition with complex interactions between multiple co-existing, and highly correlated, factors that preclude a clear assessment of the independent clinical markers and pathophysiological drivers for diabetic osteopathy. Additionally, fracture risk calculators and routinely used clinical bone measurements generally underestimate fracture risk in people with diabetes. In the absence of dedicated prospective studies including detailed bone and metabolic characteristics, optimal management centres around selecting treatments that minimise skeletal and metabolic harm. This review summarises the clinical landscape of diabetic osteopathy and outlines the interplay between metabolic and skeletal health. The underlying pathophysiology of skeletal fragility in diabetes and a rationale for considering a diabetes-based paradigm in assessing and managing diabetic bone disease will be discussed.

Citing Articles

Effect of Chrysin, a Flavonoid Present in Food, on the Skeletal System in Rats with Experimental Type 1 Diabetes.

Klasik-Ciszewska S, Londzin P, Grzywnowicz K, Borymska W, Zych M, Kaczmarczyk-Zebrowska I Nutrients. 2025; 17(2).

PMID: 39861446 PMC: 11767798. DOI: 10.3390/nu17020316.


Bone Loss in Diabetes Mellitus: Diaporosis.

Kupai K, Kang H, Posa A, Csonka A, Varkonyi T, Valkusz Z Int J Mol Sci. 2024; 25(13).

PMID: 39000376 PMC: 11242219. DOI: 10.3390/ijms25137269.

References
1.
Iepsen E, Lundgren J, Hartmann B, Pedersen O, Hansen T, Jorgensen N . GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. J Clin Endocrinol Metab. 2015; 100(8):2909-17. DOI: 10.1210/jc.2015-1176. View

2.
Tanaka K, Kanazawa I, Kaji H, Sugimoto T . Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Bone. 2016; 95:5-10. DOI: 10.1016/j.bone.2016.11.007. View

3.
Bhattacharya S, Nagendra L, Chandran M, Kapoor N, Patil P, Dutta D . Trabecular bone score in adults with type 1 diabetes: a meta-analysis. Osteoporos Int. 2023; 35(1):105-115. DOI: 10.1007/s00198-023-06935-z. View

4.
Leanza G, Maddaloni E, Pitocco D, Conte C, Palermo A, Maurizi A . Risk factors for fragility fractures in type 1 diabetes. Bone. 2019; 125:194-199. DOI: 10.1016/j.bone.2019.04.017. View

5.
Starup-Linde J, Vestergaard P . Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2015; 82:69-78. DOI: 10.1016/j.bone.2015.02.019. View